Letter from the Chairman

Dear friends, partners, and fellow believers in the power of science,

For over twelve years, Origent has operated behind the scenes of ALS drug development, using artificial intelligence to bring clarity to one of medicine’s most unpredictable diseases. ALS is uniquely challenging —every patient progresses differently, making it difficult to design effective clinical trials. This variability is a key reason why so many trials fail and so few therapies have reached the people who urgently need them.

Our team has built AI models that can forecast ALS progression using only baseline data from clinical trials. These models have been used by trial sponsors around the world to increase statistical power, reduce costs, and accelerate timelines. Our services drive impact, and are trusted by leading institutions including Massachusetts General Hospital, Emory, Mayo Clinic, and Columbia University.

But as we embedded ourselves deeper in the clinical trial space, a stark truth emerged: by the time many patients reach these studies, it’s often already too late. The average time to an ALS diagnosis is 10 to 15 months — a delay that shortens lives, limits access to treatment, and wastes precious data.

So we’re moving upstream.

We’re launching two new products to change the ALS timeline:

• ForecastOne® – A clinical decision support tool embedded in EHRs to help neurologists detect ALS earlier, with AI-powered referrals.
• MyJourney – A patient-facing app that captures their lived experience and transforms it into structured insights, guiding them to the right care sooner and enriching research datasets.

And ALS is only the beginning. We’re already preparing to scale our models into other neurodegenerative diseases—Alzheimer’s, Huntington’s, and Parkinson’s—where diagnosis is slow, care is fragmented, and too many patient stories remain unheard.

To fund this next chapter, we’re raising $3–5 million. These funds will allow us to:

• Grow our services team to support more ALS and non-ALS trials
• Launch ForecastOne into neurology clinics in the U.S. and abroad
• Deploy MyJourney and begin building a new real-world dataset from patient lived experiences

If you’ve ever been close to ALS—or to the challenge of any disease where time is precious—you understand the urgency. And if you share our belief that AI can not only power science, but also serve patients, I’d love to hear from you.

Join us. Help us change the timeline. Let’s give patients their future back—one day earlier at a time.

With gratitude,

Fabián E. Rosado
Co-Founder & Executive Chairman
Origent Data Sciences
info@origent.com
(703) 794-3041
www.origent.com